Introduction to the genetics and biology of interleukin-28B

A Polymorphism in IL28B Distinguishes Exposed, Uninfected Individuals From Spontaneous Resolvers of HCV Infection

(2011) Susanne Knapp et al.   GASTROENTEROLOGY

Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus

(2011) Nobuhiko Hiraga et al.   HEPATOLOGY

Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C

(2011) Lucy Golden-Mason et al.   HEPATOLOGY

Host genomics and HCV treatment response

(2011) Paul J Clark et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C

(2011) P.-Y. Bochud et al.   JOURNAL OF HEPATOLOGY

IL28B single nucleotide polymorphisms in the treatment of hepatitis C

(2011) Christian M. Lange et al.   JOURNAL OF HEPATOLOGY

Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1

(2011) Charles D. Howell et al.   JOURNAL OF HEPATOLOGY

Interleukin 28B Gene Variation at rs12979860 Determines Early Viral Kinetics During Treatment in Patients Carrying Genotypes 2 or 3 of Hepatitis C Virus

(2011) Magnus Lindh et al.   JOURNAL OF INFECTIOUS DISEASES

IL28B Genotype Effects During Early Treatment with Peginterferon and Ribavirin in Difficult-to-Treat Hepatitis C Virus Infection

(2011) John Scott et al.   JOURNAL OF INFECTIOUS DISEASES

IL28Bpolymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1

(2011) M. Lindh et al.   JOURNAL OF VIRAL HEPATITIS

Complexity and Catalytic Efficiency of Hepatitis C Virus (HCV) NS3 and NS4A Protease Quasispecies Influence Responsiveness to Treatment with Pegylated Interferon plus Ribavirin in HCV/HIV-Coinfected Patients

(2011) E. Aparicio et al.   JOURNAL OF VIROLOGY

USP18-Based Negative Feedback Control Is Induced by Type I and Type III Interferons and Specifically Inactivates Interferon α Response

(2011) Véronique François-Newton et al.   PLoS One

Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy

(2011) Ching-Sheng Hsu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Understanding the nature of early HCV RNA blips and the use of mathematical modeling of viral kinetics during IFN-based therapy

(2011) J. Guedj et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IL28B, HLA-C, and KIR Variants Additively Predict Response to Therapy in Chronic Hepatitis C Virus Infection in a European Cohort: A Cross-Sectional Study

(2011) Vijayaprakash Suppiah et al.   PLOS MEDICINE

A Model Explaining the Correlations Between IL28B-Related Genotypes, Hepatitis C Virus Genotypes, and Viral RNA Levels

(2010) Magnus Lindh et al.   GASTROENTEROLOGY

Hepatic ISG Expression Is Associated With Genetic Variation in Interleukin 28B and the Outcome of IFN Therapy for Chronic Hepatitis C

(2010) Masao Honda et al.   GASTROENTEROLOGY

Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study

(2010) Andri Rauch et al.   GASTROENTEROLOGY

Interferon-Induced Gene Expression Is a Stronger Predictor of Treatment Response Than IL28B Genotype in Patients With Hepatitis C

(2010) Michael T. Dill et al.   GASTROENTEROLOGY

IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C

(2010) Thomas J. Urban et al.   HEPATOLOGY

Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection

(2010) Michael R. Charlton et al.   HEPATOLOGY

Hepatitis C pharmacogenetics: State of the art in 2010

(2010) Nezam H. Afdhal et al.   HEPATOLOGY

IL28B inhibits hepatitis C virus replication through the JAK–STAT pathway

(2010) Leiliang Zhang et al.   JOURNAL OF HEPATOLOGY

Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus

(2009) Susanne Knapp et al.   HEPATOLOGY

643 PEG-IFN-l: ANTIVIRAL ACTIVITY AND SAFETY PROFILE IN A 4-WEEK PHASE 1B STUDY IN RELAPSED GENOTYPE 1 HEPATITIS C INFECTION

(2009) M. Shiffman et al.   JOURNAL OF HEPATOLOGY

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

(2009) Dongliang Ge et al.   NATURE

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

(2009) David L. Thomas et al.   NATURE

IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy

(2009) Vijayaprakash Suppiah et al.   NATURE GENETICS

Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C

(2009) Yasuhito Tanaka et al.   NATURE GENETICS

Pegylated Interferon‐α‐2a plus Ribavirin for Treatment‐Naive Asian Patients with Hepatitis C Virus Genotype 1 Infection: A Multicenter, Randomized Controlled Trial

(2008) Chen‐Hua Liu et al.   CLINICAL INFECTIOUS DISEASES

Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C

(2008) J. McHutchison et al.   JOURNAL OF VIRAL HEPATITIS

Interferon signaling and treatment outcome in chronic hepatitis C

(2008) M. Sarasin-Filipowicz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Treatment responses in Asians and Caucasians with chronic hepatitis C infection

(2008) Kenneth K Yan et al.   WORLD JOURNAL OF GASTROENTEROLOGY